Verismo Therapeutics Unveils Blood Cancer CAR-T Preclinical Data at AACR

Verismo Therapeutics is showcasing its latest preclinical findings for a blood cancer CAR-T therapy at the AACR annual meeting. The data focuses on the efficacy and potential of their next-generation cell therapy platform before moving into human trials. While these are early-stage results, they represent a significant step in addressing hard-to-treat hematologic malignancies. Industry watchers are now looking for signs that this approach can outperform current market standards.